Allogeneic stem cell transplantation

There are no reports summarizing the experience with SCT in aCML, and the lack of experience is reflected in a recent review of the results of SCT in MPD.65 With no curative option and generally poor control of aCML with currently available modalities, SCT should be considered in younger patients with available HLA-matched donors and particularly in those presenting with unfavorable risk factors.56 As with other rare disorders, the preferable use of investigational treatment modalities should be in the context of clinical trials.

0 0

Post a comment